{"product_id":"immunology-for-life-scientists-9780470845240","title":"Immunology for Life Scientists","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eThis thoroughly revised and updated new edition provides outstanding coverage of the most important aspects of immunology. Assuming no previous knowledge of the subject, the book gives step--by--step detail on topics such as antigens, hypersensitivity, autoimmunity, reproductive immunity and immunodeficiency.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cb\u003ePreface.\u003c\/b\u003e  \u003cp\u003e\u003cb\u003ePreface to the 1st Edition.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eGlossary.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 Cells and tissues of the immune system.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1.1 Cells involved in the immune response.\u003c\/p\u003e \u003cp\u003e1.1.1 Cellular origins – the pluripotent stem cell.\u003c\/p\u003e \u003cp\u003e1.1.2 Cells principally involved in the innate immune response.\u003c\/p\u003e \u003cp\u003ePolymorphonuclear leukocytes.\u003c\/p\u003e \u003cp\u003eNeutrophils.\u003c\/p\u003e \u003cp\u003eEosinophils.\u003c\/p\u003e \u003cp\u003eBasophils and mast cells.\u003c\/p\u003e \u003cp\u003eMegakaryocytes and platelets.\u003c\/p\u003e \u003cp\u003e1.1.3 Antigen presenting cells and large granular lymphocytes.\u003c\/p\u003e \u003cp\u003eMonocytes and macrophages.\u003c\/p\u003e \u003cp\u003eDendritic cells.\u003c\/p\u003e \u003cp\u003eLarge granular lymphocytes.\u003c\/p\u003e \u003cp\u003e1.1.4 Cells involved in the specific immune response.\u003c\/p\u003e \u003cp\u003eLymphocytes.\u003c\/p\u003e \u003cp\u003eT cells.\u003c\/p\u003e \u003cp\u003eB cells.\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003e1.2 Lymphoid tissues.\u003c\/p\u003e \u003cp\u003e1.2.1 Primary lymphoid tissues.\u003c\/p\u003e \u003cp\u003eThe thymus.\u003c\/p\u003e \u003cp\u003eMammalian \"bursa equivalents\".\u003c\/p\u003e \u003cp\u003eB cell development in the bone marrow.\u003c\/p\u003e \u003cp\u003e1.2.2 Secondary lymphoid tissues.\u003c\/p\u003e \u003cp\u003eThe lymphatic system.\u003c\/p\u003e \u003cp\u003eLymph nodes.\u003c\/p\u003e \u003cp\u003eSpleen.\u003c\/p\u003e \u003cp\u003e1.2.3 Tertiary lymphoid tissues.\u003c\/p\u003e \u003cp\u003eMucosa-associated lymphoid tissue.\u003c\/p\u003e \u003cp\u003eIntraepithelial lymphocytes.\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003eBibliography.\u003c\/p\u003e \u003cp\u003eNow test yourself!\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Antigens and their receptors.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e2.1 Characteristics of antigens and immunogens.\u003c\/p\u003e \u003cp\u003e2.1.1 Factors affecting immunogenicity.\u003c\/p\u003e \u003cp\u003eForeignness.\u003c\/p\u003e \u003cp\u003eSize.\u003c\/p\u003e \u003cp\u003eChemical complexity.\u003c\/p\u003e \u003cp\u003eRoute of administration.\u003c\/p\u003e \u003cp\u003eDose.\u003c\/p\u003e \u003cp\u003eHost genetic make-up.\u003c\/p\u003e \u003cp\u003eApproaches used to increase immunogenicity.\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003e2.2 The major histocompatibility factor.\u003c\/p\u003e \u003cp\u003e2.2.1 Class I MHC molecules.\u003c\/p\u003e \u003cp\u003e2.2.2 Class II MHC molecules.\u003c\/p\u003e \u003cp\u003e2.2.3 Non-classical HLA molecules.\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003e2.3 Antigen receptors on cells.\u003c\/p\u003e \u003cp\u003e2.3.1 The B cell antigen receptor.\u003c\/p\u003e \u003cp\u003eImmunoglobulins.\u003c\/p\u003e \u003cp\u003eAntibody structure.\u003c\/p\u003e \u003cp\u003eIsotypes.\u003c\/p\u003e \u003cp\u003eAllotypes.\u003c\/p\u003e \u003cp\u003eIdiotypes.\u003c\/p\u003e \u003cp\u003e2.3.2 Antibody classes.\u003c\/p\u003e \u003cp\u003eImmunoglobulin G.\u003c\/p\u003e \u003cp\u003eImmunoglobulin M.\u003c\/p\u003e \u003cp\u003eImmunoglobulin A.\u003c\/p\u003e \u003cp\u003eImmunoglobulin D.\u003c\/p\u003e \u003cp\u003eImmunoglobulin E.\u003c\/p\u003e \u003cp\u003e2.3.3 Antibody function.\u003c\/p\u003e \u003cp\u003e2.3.4 Fc receptors.\u003c\/p\u003e \u003cp\u003e2.3.5 The T cell antigen receptor.\u003c\/p\u003e \u003cp\u003eg d T cells.\u003c\/p\u003e \u003cp\u003eThe CD3 complex.\u003c\/p\u003e \u003cp\u003eFunction of the TCR–CD3 complex.\u003c\/p\u003e \u003cp\u003e2.3.6 The natural killer cell receptor.\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003e2.4 Generation of antigen receptor diversity.\u003c\/p\u003e \u003cp\u003e2.4.1 Theories concerning antibody diversity.\u003c\/p\u003e \u003cp\u003e2.4.2 The genetic basis of antibody diversity\u003c\/p\u003e \u003cp\u003eV, D and J region heavy chain genes.\u003c\/p\u003e \u003cp\u003eThe light chain V and J genes.\u003c\/p\u003e \u003cp\u003e2.4.3 Generation of antibody diversity.\u003c\/p\u003e \u003cp\u003eCombinatorial and junctional diversity.\u003c\/p\u003e \u003cp\u003eControl of VDJ gene rearrangement.\u003c\/p\u003e \u003cp\u003eMechanisms of V(D)J rearrangement.\u003c\/p\u003e \u003cp\u003eDiversity due to somatic mutation.\u003c\/p\u003e \u003cp\u003e2.4.4 Antibody maturation.\u003c\/p\u003e \u003cp\u003e2.4.5 Genetic basis of T cell antigen receptor diversity.\u003c\/p\u003e \u003cp\u003e\"Similarity to self rule\" – limited diversity.\u003c\/p\u003e \u003cp\u003eDiverse TCR repertoire.\u003c\/p\u003e \u003cp\u003eGenomic organisation – the TCRa chain.\u003c\/p\u003e \u003cp\u003eGenomic organisation – the TCRb chain.\u003c\/p\u003e \u003cp\u003eGenomic organisation – the TCRg chain.\u003c\/p\u003e \u003cp\u003eGenomic organisation – the TCRd chain.\u003c\/p\u003e \u003cp\u003e2.4.6 Generation of T cell antigen receptor diversity.\u003c\/p\u003e \u003cp\u003eSize of the T cell repertoire.\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003eBibliography.\u003c\/p\u003e \u003cp\u003eNow test yourself!\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 The innate immune response.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e3.1 The complement cascades.\u003c\/p\u003e \u003cp\u003e3.1.1 The classical complement pathway.\u003c\/p\u003e \u003cp\u003eC1.\u003c\/p\u003e \u003cp\u003eC4.\u003c\/p\u003e \u003cp\u003eC2.\u003c\/p\u003e \u003cp\u003eC3.\u003c\/p\u003e \u003cp\u003e3.1.2 The alternative complement pathway.\u003c\/p\u003e \u003cp\u003e3.1.3 The lectin pathway.\u003c\/p\u003e \u003cp\u003e3.1.4 The membrane attack complex.\u003c\/p\u003e \u003cp\u003e3.1.5 Regulation of complement activation.\u003c\/p\u003e \u003cp\u003eC1 inhibitor (C1INH).\u003c\/p\u003e \u003cp\u003eRegulators of complement activation (RCA) family.\u003c\/p\u003e \u003cp\u003eRegulators of the membrane attack complex.\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003e3.2 Phagocytosis.\u003c\/p\u003e \u003cp\u003e3.2.1 Pattern recognition receptors.\u003c\/p\u003e \u003cp\u003eComplement receptor 3 (CR3).\u003c\/p\u003e \u003cp\u003eCD14.\u003c\/p\u003e \u003cp\u003eToll-like receptors.\u003c\/p\u003e \u003cp\u003eMacrophage scavenger receptors.\u003c\/p\u003e \u003cp\u003e3.2.2 Opsonisation.\u003c\/p\u003e \u003cp\u003e3.2.3 Ingestion.\u003c\/p\u003e \u003cp\u003e3.2.4 Digestion.\u003c\/p\u003e \u003cp\u003e3.2.5 The respiratory burst.\u003c\/p\u003e \u003cp\u003e3.2.6 Other antimicrobial activities of lysosomes.\u003c\/p\u003e \u003cp\u003eDefensins.\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003e3.3 Inflammation.\u003c\/p\u003e \u003cp\u003e3.3.1 Inflammatory mediators.\u003c\/p\u003e \u003cp\u003e3.3.2 Cellular responses in inflammation.\u003c\/p\u003e \u003cp\u003e3.3.3 Chemokines.\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003e3.4 Haemostasis and thrombosis.\u003c\/p\u003e \u003cp\u003e3.4.1 Regulation of coagulation.\u003c\/p\u003e \u003cp\u003e3.4.2 The fibrinolytic system.\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003eBibliography.\u003c\/p\u003e \u003cp\u003eNow test yourself!\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 The adaptive immune response.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e4.1 Antigen processing and presentation by MHC gene products.\u003c\/p\u003e \u003cp\u003e4.1.1 Generation of peptides presented by MHC Class I molecules.\u003c\/p\u003e \u003cp\u003eAssembly and intracellular transport of MHC Class I molecules.\u003c\/p\u003e \u003cp\u003e4.1.2 Generation of peptides presented by MHC Class II molecules.\u003c\/p\u003e \u003cp\u003eAssembly and intracellular transport of MHC Class II molecules.\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003e4.2 Antigen processing and presentation by CD1.\u003c\/p\u003e \u003cp\u003e4.2.1 Structure of CD1.\u003c\/p\u003e \u003cp\u003e4.2.2 Antigen presentation by CD1.\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003e4.3 Cell-mediated immunity.\u003c\/p\u003e \u003cp\u003e4.3.1 Antigen-specific T cell stimulation.\u003c\/p\u003e \u003cp\u003eT cell responses to antigen stimulation.\u003c\/p\u003e \u003cp\u003eTh\u003csub\u003e0\u003c\/sub\u003e, Th\u003csub\u003e1\u003c\/sub\u003e and Th\u003csub\u003e2\u003c\/sub\u003e cells.\u003c\/p\u003e \u003cp\u003e4.3.2 Other cells in cell-mediated immunity.\u003c\/p\u003e \u003cp\u003eMechanisms of target cell death.\u003c\/p\u003e \u003cp\u003eCytotoxic T cells.\u003c\/p\u003e \u003cp\u003eMacrophages.\u003c\/p\u003e \u003cp\u003eNK cells.\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003e4.4 Cell adaptive immunity.\u003c\/p\u003e \u003cp\u003e4.4.1 B cell differentiation and antibody production.\u003c\/p\u003e \u003cp\u003eClass switching.\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003e4.5 Lymphocyte memory.\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003e4.6 The mucosal immune response.\u003c\/p\u003e \u003cp\u003e4.6.1 Structure of the mucosal immune system.\u003c\/p\u003e \u003cp\u003eOrganised mucosal lymphoid tissue.\u003c\/p\u003e \u003cp\u003eIntraepithelial cells.\u003c\/p\u003e \u003cp\u003eLeukocytes in the lamina propria.\u003c\/p\u003e \u003cp\u003e4.6.2 Immunoglobulins and mucosal immunity.\u003c\/p\u003e \u003cp\u003eProduction of other immunoglobulins in the mucosa.\u003c\/p\u003e \u003cp\u003e4.6.3 The mucosae and their role in immunity.\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003e4.7 Tolerance.\u003c\/p\u003e \u003cp\u003e4.7.1 Lymphocyte tolerance.\u003c\/p\u003e \u003cp\u003eInduction time.\u003c\/p\u003e \u003cp\u003eAntigen dose.\u003c\/p\u003e \u003cp\u003eAntigen persistence.\u003c\/p\u003e \u003cp\u003eSpecificity.\u003c\/p\u003e \u003cp\u003eDuration.\u003c\/p\u003e \u003cp\u003eRoute of administration.\u003c\/p\u003e \u003cp\u003eTissue specificity.\u003c\/p\u003e \u003cp\u003e4.7.2 Mechanisms of tolerance induction.\u003c\/p\u003e \u003cp\u003eClonal deletion.\u003c\/p\u003e \u003cp\u003eClonal anergy.\u003c\/p\u003e \u003cp\u003eClonal exhaustion.\u003c\/p\u003e \u003cp\u003eClonal abortion.\u003c\/p\u003e \u003cp\u003eAntibody forming cell (AFC) blockade.\u003c\/p\u003e \u003cp\u003e4.7.3 Maintenance of tolerance.\u003c\/p\u003e \u003cp\u003eRegulatory T cells.\u003c\/p\u003e \u003cp\u003eAntibody-induced tolerance.\u003c\/p\u003e \u003cp\u003e4.7.4 Mechanisms involved in the development of incomplete tolerance.\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003eBibliography.\u003c\/p\u003e \u003cp\u003eNow test yourself!\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Abnormalities of the immune system.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e5.1 Hypersensitivity.\u003c\/p\u003e \u003cp\u003e5.1.1 Hypersensitivity reactions.\u003c\/p\u003e \u003cp\u003e5.1.2 Type I hypersensitivity.\u003c\/p\u003e \u003cp\u003eRegulation of Type I hypersensitivity.\u003c\/p\u003e \u003cp\u003eHumoral events in allergy.\u003c\/p\u003e \u003cp\u003e5.1.3 Type II hypersensitivity.\u003c\/p\u003e \u003cp\u003e5.1.4 Type III hypersensitivity.\u003c\/p\u003e \u003cp\u003e5.1.5 Type IV hypersensitivity.\u003c\/p\u003e \u003cp\u003eTuberculin-type DTH.\u003c\/p\u003e \u003cp\u003eGranuloma formation.\u003c\/p\u003e \u003cp\u003eContact hypersensitivity.\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003e5.2 Autoimmunity and autoimmune diseases.\u003c\/p\u003e \u003cp\u003e5.2.1 Causes of autoimmunity.\u003c\/p\u003e \u003cp\u003eGenetic factors in autoimmune disease.\u003c\/p\u003e \u003cp\u003eSex-linked factors in autoimmune disease.\u003c\/p\u003e \u003cp\u003eStress and neurochemicals in autoimmune disease.\u003c\/p\u003e \u003cp\u003eChemicals and pharmaceuticals in autoimmune disease.\u003c\/p\u003e \u003cp\u003eViruses in autoimmune disease.\u003c\/p\u003e \u003cp\u003eAntigen mimicry.\u003c\/p\u003e \u003cp\u003e5.2.2 Classification of autoimmune disease.\u003c\/p\u003e \u003cp\u003e5.2.3 Immunopathology of autoimmune diseases.\u003c\/p\u003e \u003cp\u003e5.2.4 The immunology of autoimmune disease.\u003c\/p\u003e \u003cp\u003eTarget antigens.\u003c\/p\u003e \u003cp\u003eNon-specific immunity in autoimmune disease.\u003c\/p\u003e \u003cp\u003eMononuclear phagocytes in non-specific immunity.\u003c\/p\u003e \u003cp\u003eMononuclear phagocytes in specific immunity.\u003c\/p\u003e \u003cp\u003eDendritic cells in autoimmune disease.\u003c\/p\u003e \u003cp\u003eRole of T cells in autoimmune disease.\u003c\/p\u003e \u003cp\u003eB cells in autoimmune disease.\u003c\/p\u003e \u003cp\u003eCytokine defects.\u003c\/p\u003e \u003cp\u003eChemokines in autoimmune disease.\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003e5.3 Immunodeficiency diseases.\u003c\/p\u003e \u003cp\u003e5.3.1 Classification of immunodeficiency diseases.\u003c\/p\u003e \u003cp\u003e5.3.2 Primary immunodeficiency diseases.\u003c\/p\u003e \u003cp\u003e5.3.3 B cell abnormalities.\u003c\/p\u003e \u003cp\u003eSelective immunoglobulin A deficiency.\u003c\/p\u003e \u003cp\u003eX-linked agammaglobulinaemia (XLA).\u003c\/p\u003e \u003cp\u003eCD40 ligand deficiency.\u003c\/p\u003e \u003cp\u003eX-linked lymphoproliferative disease (Duncan’s syndrome).\u003c\/p\u003e \u003cp\u003e5.3.4 T cell abnormalities.\u003c\/p\u003e \u003cp\u003eCongenital thymic aplasia (Di George syndrome).\u003c\/p\u003e \u003cp\u003eWiskott–Aldrich syndrome.\u003c\/p\u003e \u003cp\u003e5.3.5 T and B cell abnormalities.\u003c\/p\u003e \u003cp\u003eSevere combined immunodeficiency disease (SCID).\u003c\/p\u003e \u003cp\u003eX-linked severe combined immunodeficiency disease (XSCID).\u003c\/p\u003e \u003cp\u003eSCID with adenosine deaminase deficiency (ADA-SCID).\u003c\/p\u003e \u003cp\u003eThe bare lymphocyte syndrome.\u003c\/p\u003e \u003cp\u003e5.3.6 Abnormalities associated with phagocytic cells.\u003c\/p\u003e \u003cp\u003eChediak–Higashi syndrome (CHS).\u003c\/p\u003e \u003cp\u003eChronic granulomatous disease (CGD).\u003c\/p\u003e \u003cp\u003e5.3.7 Abnormalities of the complement pathway.\u003c\/p\u003e \u003cp\u003eDeficiencies of complement components.\u003c\/p\u003e \u003cp\u003eThe alternative pathway.\u003c\/p\u003e \u003cp\u003eThe classical pathway.\u003c\/p\u003e \u003cp\u003eC1INH deficiency – hereditary angioedema (HAE).\u003c\/p\u003e \u003cp\u003e5.3.8 Acquired immunodeficiencies.\u003c\/p\u003e \u003cp\u003eIatrogenic immunodeficiencies.\u003c\/p\u003e \u003cp\u003e5.3.9 The acquired immunodeficiency syndrome (AIDS).\u003c\/p\u003e \u003cp\u003eThe human immunodeficiency virus (HIV).\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003eBibliography.\u003c\/p\u003e \u003cp\u003eNow test yourself!\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Infection, immunity, immunopathogenesis.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e6.1 The innate immune system in infection.\u003c\/p\u003e \u003cp\u003e6.1.1 The skin.\u003c\/p\u003e \u003cp\u003e6.1.2 The mucosae.\u003c\/p\u003e \u003cp\u003e6.1.3 Protective chemicals.\u003c\/p\u003e \u003cp\u003eLysozyme.\u003c\/p\u003e \u003cp\u003eAlimentary fluids.\u003c\/p\u003e \u003cp\u003eComplement.\u003c\/p\u003e \u003cp\u003eDefensins.\u003c\/p\u003e \u003cp\u003eNatural antibodies.\u003c\/p\u003e \u003cp\u003e6.1.4 The role of normal body flora.\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003e6.2 Infection – the role of the innate immune system.\u003c\/p\u003e \u003cp\u003e6.2.1 Attachment.\u003c\/p\u003e \u003cp\u003e6.2.2 The body’s response to invasion – fever.\u003c\/p\u003e \u003cp\u003e6.2.3 Cells involved in innate immunity in infection.\u003c\/p\u003e \u003cp\u003ePhagocytic cells.\u003c\/p\u003e \u003cp\u003eNatural killer cells.\u003c\/p\u003e \u003cp\u003ePlatelets.\u003c\/p\u003e \u003cp\u003e6.2.4 Inflammation and immunopathology.\u003c\/p\u003e \u003cp\u003eEndotoxin.\u003c\/p\u003e \u003cp\u003eEndotoxin-induced injury.\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003e6.3 Infection – the role of the specific immune response.\u003c\/p\u003e \u003cp\u003e6.3.1 Intracellular pathogens and fungi.\u003c\/p\u003e \u003cp\u003e6.3.2 Parasitic infections.\u003c\/p\u003e \u003cp\u003e6.3.3 The role of antibody in immunity to infection.\u003c\/p\u003e \u003cp\u003eOpsonisation.\u003c\/p\u003e \u003cp\u003eComplement activation.\u003c\/p\u003e \u003cp\u003eInhibition of adherence.\u003c\/p\u003e \u003cp\u003eToxin neutralisation.\u003c\/p\u003e \u003cp\u003eVirus neutralisation.\u003c\/p\u003e \u003cp\u003eInhibition of microbial enzyme activity.\u003c\/p\u003e \u003cp\u003eInhibition of microbial growth.\u003c\/p\u003e \u003cp\u003e6.3.4 Pathology due to specific antibody.\u003c\/p\u003e \u003cp\u003ePolyclonal B cell activation.\u003c\/p\u003e \u003cp\u003eImmune complex formation.\u003c\/p\u003e \u003cp\u003e6.3.5 T cell-mediated immunity.\u003c\/p\u003e \u003cp\u003eParasitic infections.\u003c\/p\u003e \u003cp\u003eViral infections.\u003c\/p\u003e \u003cp\u003eTh\u003csub\u003e1\u003c\/sub\u003e and Th\u003csub\u003e2\u003c\/sub\u003e cells.\u003c\/p\u003e \u003cp\u003eCytotoxic T cell activity.\u003c\/p\u003e \u003cp\u003eCytolytic mechanisms.\u003c\/p\u003e \u003cp\u003e6.3.6 Pathology caused by the cell-mediated immune response.\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003e6.4 Cytokines in immunity to infection.\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003eBibliography.\u003c\/p\u003e \u003cp\u003eNow test yourself!\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Immunity and the MHC.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e7.1 Transplantation.\u003c\/p\u003e \u003cp\u003e7.1.1 Tissue typing.\u003c\/p\u003e \u003cp\u003e7.1.2 Cross-matching.\u003c\/p\u003e \u003cp\u003e7.1.3 Rejection.\u003c\/p\u003e \u003cp\u003eDirect allorecognition.\u003c\/p\u003e \u003cp\u003eIndirect allorecognition.\u003c\/p\u003e \u003cp\u003eMechanisms involved in hyperacute rejection.\u003c\/p\u003e \u003cp\u003eMechanisms involved in acute rejection.\u003c\/p\u003e \u003cp\u003eMechanisms involved in chronic rejection.\u003c\/p\u003e \u003cp\u003eThe role of the graft endothelium in rejection.\u003c\/p\u003e \u003cp\u003e7.1.4 Kidney transplantation.\u003c\/p\u003e \u003cp\u003ePre-sensitisation.\u003c\/p\u003e \u003cp\u003eCadaveric kidney transplantation.\u003c\/p\u003e \u003cp\u003e7.1.5 Liver transplantation.\u003c\/p\u003e \u003cp\u003eProcedure.\u003c\/p\u003e \u003cp\u003ePrimary non-function and rejection.\u003c\/p\u003e \u003cp\u003e7.1.6 Heart transplantation.\u003c\/p\u003e \u003cp\u003eRejection.\u003c\/p\u003e \u003cp\u003e7.1.7 Bone marrow transplantation.\u003c\/p\u003e \u003cp\u003e7.1.8 Pancreas transplantation.\u003c\/p\u003e \u003cp\u003e7.1.9 Xenotransplantation.\u003c\/p\u003e \u003cp\u003eChoice of donor.\u003c\/p\u003e \u003cp\u003eBarriers to xenotransplantation.\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003e7.2 The immunology of reproduction.\u003c\/p\u003e \u003cp\u003e7.2.1 The development of maternal and foetal tissues.\u003c\/p\u003e \u003cp\u003e7.2.2 Female reproductive immunology.\u003c\/p\u003e \u003cp\u003e7.2.3 Maternal–foetal exchange.\u003c\/p\u003e \u003cp\u003e7.2.4 Effect of pregnancy on the maternal immune response.\u003c\/p\u003e \u003cp\u003ePeripheral immunity.\u003c\/p\u003e \u003cp\u003eFoetal–uterine immunity.\u003c\/p\u003e \u003cp\u003e7.2.5 Cytokine–endocrine relationship in pregnancy.\u003c\/p\u003e \u003cp\u003eOestrogen and progesterone.\u003c\/p\u003e \u003cp\u003eHuman chorionic gonadotrophin.\u003c\/p\u003e \u003cp\u003e7.2.6 Immunity to infection in pregnancy.\u003c\/p\u003e \u003cp\u003e7.2.7 Immunocompetent cells in the decidua.\u003c\/p\u003e \u003cp\u003eLarge granular lymphocytes.\u003c\/p\u003e \u003cp\u003eMacrophages.\u003c\/p\u003e \u003cp\u003eDecidual antigen presenting cells.\u003c\/p\u003e \u003cp\u003eT lymphocytes.\u003c\/p\u003e \u003cp\u003e7.2.8 Recurrent, spontaneous, abortion\u003c\/p\u003e \u003cp\u003e7.2.9 The immunology of male reproduction.\u003c\/p\u003e \u003cp\u003eThe blood–testis barrier.\u003c\/p\u003e \u003cp\u003eSperm-specific antigens.\u003c\/p\u003e \u003cp\u003eImmunologically active cells in semen.\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003eBibliography.\u003c\/p\u003e \u003cp\u003eNow test yourself!\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Other diseases.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e8.1 Atherosclerosis.\u003c\/p\u003e \u003cp\u003e8.1.1 Normal arterial wall.\u003c\/p\u003e \u003cp\u003e8.1.2 Extracellular matrix.\u003c\/p\u003e \u003cp\u003e8.1.3 Pathogenesis of atherosclerosis.\u003c\/p\u003e \u003cp\u003eRole of lipoproteins in atherosclerosis.\u003c\/p\u003e \u003cp\u003e8.1.4 Plaque development.\u003c\/p\u003e \u003cp\u003e8.1.5 Mononuclear cells in atherosclerosis – macrophages and dendritic cells.\u003c\/p\u003e \u003cp\u003e8.1.6 Mononuclear cells in atherosclerosis – T cells.\u003c\/p\u003e \u003cp\u003e8.1.7 Mononuclear cells in atherosclerosis – B cells.\u003c\/p\u003e \u003cp\u003e8.1.8 Other immune cells in atherosclerotic plaques.\u003c\/p\u003e \u003cp\u003e8.1.9 Cytokines in atherosclerosis.\u003c\/p\u003e \u003cp\u003e8.1.10 Is atherosclerosis an autoimmune disease?\u003c\/p\u003e \u003cp\u003ePotential autoantigens.\u003c\/p\u003e \u003cp\u003e8.1.11 Infection and atherosclerosis.\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003e8.2 Tumour immunology.\u003c\/p\u003e \u003cp\u003e8.2.1 The nature of malignant disease.\u003c\/p\u003e \u003cp\u003e8.2.2 Causes of malignancy.\u003c\/p\u003e \u003cp\u003ePhysical carcinogens.\u003c\/p\u003e \u003cp\u003eChemical carcinogens.\u003c\/p\u003e \u003cp\u003eViral carcinogens.\u003c\/p\u003e \u003cp\u003eOncogenes.\u003c\/p\u003e \u003cp\u003e8.2.3 Tumour antigens.\u003c\/p\u003e \u003cp\u003eMelanoma–melanocyte differentiation antigens (MMDAs).\u003c\/p\u003e \u003cp\u003eCancer testes antigens (CTAs).\u003c\/p\u003e \u003cp\u003eRenal carcinoma antigen.\u003c\/p\u003e \u003cp\u003eNon-mutated shared antigens.\u003c\/p\u003e \u003cp\u003eMutated antigens.\u003c\/p\u003e \u003cp\u003e8.2.4 Tumour suppressor gene – oncogene networks.\u003c\/p\u003e \u003cp\u003e8.2.5 Tumour immunology.\u003c\/p\u003e \u003cp\u003eInnate immunity.\u003c\/p\u003e \u003cp\u003eInflammation and the development of cancer.\u003c\/p\u003e \u003cp\u003eSpecific immunity.\u003c\/p\u003e \u003cp\u003eTumour cell evasion of the immune response.\u003c\/p\u003e \u003cp\u003e8.2.6 Cancer biotherapy.\u003c\/p\u003e \u003cp\u003eAnti-tumour vaccines.\u003c\/p\u003e \u003cp\u003eAnti-idiotypic antibodies.\u003c\/p\u003e \u003cp\u003eBiological response modifiers (BRM).\u003c\/p\u003e \u003cp\u003eKey points for review.\u003c\/p\u003e \u003cp\u003eBibliography\u003c\/p\u003e \u003cp\u003eNow test yourself!\u003c\/p\u003e \u003cp\u003e\u003cb\u003eAnswers to \"now test yourself!\"\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eIndex.\u003c\/b\u003e\u003c\/p\u003e","brand":"John Wiley \u0026 Sons Inc","offers":[{"title":"Default Title","offer_id":49402437370199,"sku":"9780470845240","price":62.65,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780470845240.jpg?v=1730480395","url":"https:\/\/bookcurl.com\/products\/immunology-for-life-scientists-9780470845240","provider":"Book Curl","version":"1.0","type":"link"}